Rapport Therapeutics
RAPP
77 hedge funds and large institutions have $382M invested in Rapport Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 9 reducing their positions, and 9 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 9
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
10% more funds holding
Funds holding: 70 → 77 (+7)
4.4% more ownership
Funds ownership: 99.99% → 104.39% (+4.4%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
41% less capital invested
Capital invested by funds: $649M → $382M (-$267M)
50% less call options, than puts
Call options by funds: $10K | Put options by funds: $20K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.27M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$5.94M |
| 3 |
BlackRock
New York
|
+$5.33M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$2.64M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.53M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.09M |
| 3 |
Jennison Associates
New York
|
-$1.1M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$911K |
RAPP Hedge Fund Activity: Q1 2025 in Review
77 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q1 2025, worth a combined $382M — down 41% from $649M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RAPP positions and 9 closed out — a net gain of 7 holders — while 36 added to existing stakes and 9 trimmed.
The largest buyer was Vanguard Group, adding an estimated $7.27M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $5.53M sold.
- 77 institutional investors held Rapport Therapeutics (RAPP) as of Q1 2025, up from 70 in Q4 2024.
- Funds reported $382M of Rapport Therapeutics stock for Q1 2025, down 41% quarter-over-quarter.
- 16 funds opened new Rapport Therapeutics positions in Q1 2025 and 9 closed out, a net change of +7 holders.
- The largest Rapport Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $7.27M added.
- The largest Rapport Therapeutics seller in Q1 2025 was Perceptive Advisors, an estimated $5.53M sold.
Based on aggregated 13F filings for Q1 2025.